, /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.
This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:
Tuesday, August 4, 2026
Starting at 5:00 p.m. EDT
Webcast can be accessed using this link
Dial in number: 877-918-6630
International dial in: 517-308-9042
When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay.
About DaVita Inc.
DaVita (NYSE: DVA) is a healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey — from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of March 31, 2026, DaVita served approximately 296,300 patients at 3,262 outpatient dialysis centers, of which 2,666 centers were located in the United States and 596 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $236.97, marking a +1.26% move from the previous day. This move outpaced the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
The stock of kidney dialysis provider has risen by 12.55% in the past month, leading the Medical sector's gain of 5.37% and the S&P 500's gain of 0.32%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4.01, marking a 35.93% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 4.53% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $15.07 per share and a revenue of $14.3 billion, representing changes of +39.8% and +4.78%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 15.53. This signifies a discount in comparison to the average Forward P/E of 20.04 for its industry.
It is also worth noting that DVA currently has a PEG ratio of 0.77. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.71 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 162, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $234.01, demonstrating a +1.04% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.51% for the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost 1.47%.
Heading into today, shares of the kidney dialysis provider had gained 9.99% over the past month, outpacing the Medical sector's gain of 3.63% and the S&P 500's gain of 0.53%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. The company is forecasted to report an EPS of $4.01, showcasing a 35.93% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $3.53 billion, indicating a 4.53% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $15.07 per share and revenue of $14.3 billion, indicating changes of +39.8% and +4.78%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for DaVita HealthCare. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 15.37. This denotes a discount relative to the industry average Forward P/E of 19.5.
We can also see that DVA currently has a PEG ratio of 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.68.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $232.80, moving +1.45% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.42% for the day. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
Heading into today, shares of the kidney dialysis provider had gained 12.58% over the past month, outpacing the Medical sector's gain of 5.6% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $4.01, marking a 35.93% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $15.07 per share and revenue of $14.3 billion. These results would represent year-over-year changes of +39.8% and +4.78%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 15.23. Its industry sports an average Forward P/E of 19.75, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
Investors should also note that DVA has a PEG ratio of 0.75 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DVA's industry had an average PEG ratio of 1.65 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 57, positioning it in the top 24% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $230.72, marking a -1.53% move from the previous day. This change lagged the S&P 500's daily loss of 0.28%. On the other hand, the Dow registered a loss of 1.09%, and the technology-centric Nasdaq increased by 0.2%.
Shares of the kidney dialysis provider witnessed a gain of 18.23% over the previous month, beating the performance of the Medical sector with its gain of 7.8%, and the S&P 500's gain of 1.64%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is expected to report EPS of $4.01, up 35.93% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.07 per share and revenue of $14.3 billion. These totals would mark changes of +39.8% and +4.78%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 15.55. This denotes a discount relative to the industry average Forward P/E of 19.85.
We can additionally observe that DVA currently boasts a PEG ratio of 0.77. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DVA's industry had an average PEG ratio of 1.64 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 54, which puts it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
On July 02, 2026, DaVita Inc (DVA) shares rose 3.0% to a current price of $234.91. The stock has experienced significant price appreciation recently, with a 10.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is DaVita (DVA - Free Report) . DVA is currently holding a Zacks Rank #1 (Strong Buy) and a Value grade of A. The stock holds a P/E ratio of 10.65, while its industry has an average P/E of 18.26. DVA's Forward P/E has been as high as 15.44 and as low as 10.48, with a median of 13.17, all within the past year.
Investors should also note that DVA holds a PEG ratio of 0.83. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DVA's PEG compares to its industry's average PEG of 1.42. Within the past year, DVA's PEG has been as high as 1.09 and as low as 0.69, with a median of 0.87.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. DVA has a P/S ratio of 1.06. This compares to its industry's average P/S of 1.32.
These are just a handful of the figures considered in DaVita's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that DVA is an impressive value stock right now.
Key Takeaways DaVita expands kidney care via the IKC platform across CKD and ESKD dialysis network services.DVA expands digital infrastructure and AI ScheduleHub to improve dialysis scheduling efficiency.FMS expands kinexus and 5008X CAREsystem; RMTI signs dialysis supply deals with Heritage and aQua. DaVita Inc. (DVA - Free Report) , a well-known kidney care services provider, plays a central role in the dialysis ecosystem by providing comprehensive kidney care services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company operates an extensive network of outpatient dialysis centers in the United States and internationally, offering in-center dialysis, home dialysis and related clinical services. Beyond delivering dialysis treatments, DVA supports patients across the broader continuum of kidney care through integrated care programs designed to improve clinical outcomes and coordinate treatment with physicians and other healthcare providers.
As kidney care continues to shift toward value-based delivery models, DaVita is expanding its Integrated Kidney Care (IKC) platform to better manage patients with advanced kidney disease. The company reported continued progress under the Centers for Medicare & Medicaid Services' (CMS) Comprehensive Kidney Care Contracting (CKCC) program, delivering year-over-year improvements in gross savings, quality scores and high-performing status. These results highlight DVA's efforts to pair coordinated care with data-driven insights to improve patient outcomes while supporting a more sustainable kidney care model.
DaVita is also investing in technology to strengthen its dialysis operations and enhance care delivery. During 2026, the company continued expanding its digital infrastructure and AI capabilities, including the introduction of ScheduleHub, an AI-powered scheduling tool that aligns patient appointments, staffing availability and clinic capacity. By reducing administrative burden and improving operational efficiency across its dialysis centers, these investments reinforce DVA's focus on delivering high-quality, patient-centered kidney care while supporting the evolving needs of the dialysis industry.
FMS & RMTI Advancing Kidney Care DeliveryFresenius Medical Care AG (FMS - Free Report) is strengthening its foothold in kidney care by integrating dialysis services, value-based care and digital innovation across the treatment continuum. Fresenius Medical Care recently launched kinexus, a unified digital platform that supports home dialysis through remote therapy monitoring, prescription management and integrated supply ordering. Additionally, Fresenius Medical Care is accelerating the U.S. rollout of its 5008X CAREsystem, reinforcing its focus on connected, patient-centric dialysis care while expanding access to advanced home and in-center therapies.
Rockwell Medical, Inc. (RMTI - Free Report) is strengthening kidney care delivery by supplying dialysis providers with a comprehensive portfolio of hemodialysis products that support treatment across outpatient centers, skilled nursing facilities and home dialysis settings. Rockwell Medical recently signed a three-year product purchase agreement with Heritage Dialysis and renewed its agreement with aQua Dialysis, expanding access to its dialysis concentrates and ancillary products. Through these partnerships, Rockwell Medical continues to enhance the reliability and availability of dialysis care across diverse treatment settings.
DVA’s Price Performance, Valuation and EstimatesShares of DaVita have gained 93.4% year to date compared with the industry’s rise of 14.7%.
Image Source: Zacks Investment Research
DVA’s forward 12-month P/E of 13.2X is lower than the industry’s average of 18.2X but higher than its five-year median of 12.7X. It has a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DVA’s 2026 earnings per share suggests a 39.8% improvement compared with 2025.
Image Source: Zacks Investment Research
DaVita currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita Inc. (DVA - Free Report) : This kidney dialysis company has a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita Inc. has a PEG ratio of 0.71 compared with 2.36 for the industry. The company possesses a Growth Score of B.
Five Below, Inc. (FIVE - Free Report) : This specialty retail company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.1% over the last 60 days.
Five Below has a PEG ratio of 1.00 compared with 2.02 for the industry. The company possesses a Growth Score of B.
Pitney Bowes Inc. (PBI - Free Report) : This shipping and mailing services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.6% over the last 60 days.
Pitney Bowes has a PEG ratio of 0.81 compared with 0.83 for the industry. The company possesses a Growth Score of A.
See the full list of top ranked stocks here.
Learn more about the Growth score and how it is calculated here.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: DaVita HealthCare (DVA - Free Report) Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates outpatient dialysis centers and provides related services primarily in its dialysis centers and contracted hospitals across the United States, in addition to offering integrated kidney care services under value-based arrangements. Its services include outpatient dialysis services, hospital inpatient dialysis services and certain ancillary services.
DVA is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 14.4; value investors should take notice.
For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.91 to $15.07 per share. DVA boasts an average earnings surprise of +2.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, DVA should be on investors' short list.
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $217.04, moving +1.72% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.05%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.24%.
Shares of the kidney dialysis provider have appreciated by 8.25% over the course of the past month, outperforming the Medical sector's gain of 4.42%, and the S&P 500's loss of 1.42%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $4.01, showcasing a 35.93% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.07 per share and revenue of $14.3 billion. These totals would mark changes of +39.8% and +4.78%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at valuation, DaVita HealthCare is presently trading at a Forward P/E ratio of 14.16. Its industry sports an average Forward P/E of 19.05, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
We can also see that DVA currently has a PEG ratio of 0.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.6 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 69, placing it within the top 29% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 26:
LyondellBasell Industries N.V. (LYB - Free Report) : This chemical company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 60.5% over the last 60 days.
LyondellBasell has a PEG ratio of 0.13 compared with 0.60 for the industry. The company possesses a Growth Score of B.
H&R Block, Inc. (HRB - Free Report) : This DIY tax return preparation services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.
H&R Block has a PEG ratio of 0.56 compared with 1.00 for the industry. The company possesses a Growth Score of B.
DaVita Inc. (DVA - Free Report) : This dialysis services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita has a PEG ratio of 0.70 compared with 2.29 for the industry. The company possesses a Growth Score of B.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Learn more about the Growth score and how it is calculated here.
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $213.04, moving +1% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.1%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq lost 0.43%.
The kidney dialysis provider's stock has climbed by 7.85% in the past month, exceeding the Medical sector's gain of 1.97% and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. The company's upcoming EPS is projected at $4.01, signifying a 35.93% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $15.07 per share and revenue of $14.3 billion, indicating changes of +39.8% and +4.78%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DaVita HealthCare is holding a Zacks Rank of #1 (Strong Buy) right now.
Valuation is also important, so investors should note that DaVita HealthCare has a Forward P/E ratio of 14 right now. This expresses a discount compared to the average Forward P/E of 18.44 of its industry.
Also, we should mention that DVA has a PEG ratio of 0.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.54 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 56, putting it in the top 23% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Key Takeaways DVA is expanding kidney care beyond hospitals through outpatient and home-centered treatment settings.DaVita's IKC platform and CKCC results highlight its focus on value-based care and savings.AVAH and PNTG are expanding home, hospice, senior living and community-based care networks. DaVita Inc. (DVA - Free Report) , a well-known kidney care services provider, is helping reshape healthcare delivery by expanding treatment beyond traditional hospital settings and into community-based and home-centered environments. The company operates one of the largest outpatient dialysis networks in the world, serving approximately 296,300 patients through 3,262 outpatient dialysis centers as of March 2026. In addition to its clinic-based services, DVA continues to advance integrated kidney care programs that coordinate treatment across the patient journey, supporting improved outcomes while helping reduce the overall cost of care. This strategy aligns with the broader shift toward accessible, lower-cost care settings outside acute-care facilities.
DVA also maintains significant exposure to government-sponsored healthcare programs, with Medicare-related reimbursement continuing to play an important role in its business. Through its Integrated Kidney Care (IKC) platform and participation in value-based care initiatives, the company works to improve clinical outcomes while managing healthcare spending for patients with chronic kidney disease and end-stage kidney disease. Recent results from the CMS Comprehensive Kidney Care Contracting (CKCC) program reflected continued progress in savings and quality performance, underscoring the growing importance of value-based care within DVA’s operating model.
To further support care delivery, DVA continues to invest in technology and digital capabilities. Among its latest initiatives is ScheduleHub, an AI-enabled scheduling tool designed to optimize patient and staffing schedules across dialysis centers, improving operational efficiency as the company expands its data-driven approach to kidney care.
AVAH & PNTG Advancing Care Beyond Hospital SettingsAveanna Healthcare Holdings Inc. (AVAH - Free Report) provides a diversified home-care platform serving medically complex children, adults and seniors through private-duty nursing, home health, hospice and medical solutions, enabling patients to receive care in lower-cost home and community settings rather than hospitals. Aveanna Healthcare derives substantial revenues from government programs, particularly Medicare and Medicaid, and continues expanding its community-based footprint. Recently, Aveanna Healthcare announced the acquisition of Family First Homecare, strengthening its in-home pediatric care capabilities and reinforcing AVAH’s focus on cost-effective care delivery.
The Pennant Group, Inc. (PNTG - Free Report) delivers healthcare services through home health, hospice and senior living operations, emphasizing care in patients’ homes and other cost-effective post-acute settings supported by government reimbursement programs, including Medicare and Medicaid. Pennant Group derives a significant portion of revenues from these programs and benefits from the ongoing shift away from higher-cost institutional care. Recently, Pennant Group expanded its platform through the acquisition of Copper Canyon Memory Care in Arizona and the addition of three senior living communities in Arizona and Wisconsin, further enhancing PNTG’s community-based care network.
DVA’s Price Performance, Valuation and EstimatesShares of DaVita have gained 85.6% year to date compared with the industry’s rise of 9%.
Image Source: Zacks Investment Research
DVA’s forward 12-month P/E of 12.67X is lower than the industry’s average of 17.29X but higher than its five-year median of 12.65X. It has a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DVA’s 2026 earnings per share suggests a 39.8% improvement compared with 2025.
Image Source: Zacks Investment Research
DaVita currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Key Takeaways DaVita supports kidney patients through dialysis centers and integrated care programs.DVA saw year-over-year CKCC gains in gross savings rates, quality scores and status.EHC and OPCH deliver rehabilitation and infusion services outside traditional hospital settings. DaVita Inc. (DVA - Free Report) represents the growing shift in healthcare toward specialized, lower-cost care settings that help manage patients with chronic and complex conditions outside traditional acute-care hospitals. The company focuses on kidney care, providing dialysis services through a broad network of outpatient centers while also supporting patients through integrated care programs designed to improve coordination across the treatment journey. As of March 31, 2026, DVA served approximately 296,300 patients through 3,262 outpatient dialysis centers globally and had about 62,600 patients enrolled in risk-based integrated kidney care arrangements, representing roughly $5.4 billion in annualized medical spend.
Beyond dialysis delivery, DaVita continues to expand its value-based care capabilities through Integrated Kidney Care (IKC), which aims to improve patient outcomes while lowering overall healthcare costs. During first-quarter 2026, the company reported year-over-year improvements across all key measures in CMS’ Comprehensive Kidney Care Contracting (CKCC) program, including gross savings rates, quality scores and high-performing status. Management highlighted that the program generated the highest aggregate savings among participants, reflecting the benefits of coordinated, data-driven care for patients with chronic kidney disease.
Recent developments also underscore DaVita’s focus on enhancing care delivery through technology. The company is investing in digital infrastructure and AI to support clinical teams and improve operational efficiency. As part of these efforts, DVA introduced ScheduleHub, a tool that dynamically evaluates patient census, center capacity and staff availability to optimize scheduling in real time. The initiative is intended to reduce administrative burden for facility administrators and support patient care.
EHC and OPCH Delivering Complex Care Outside HospitalsEncompass Health Corporation (EHC - Free Report) extends specialized care beyond traditional acute-care hospitals through its inpatient rehabilitation network, serving patients recovering from strokes, brain injuries, spinal cord injuries, amputations and other complex conditions. Using interdisciplinary teams of nurses, therapists and physicians, Encompass Health helps patients regain function, independence and quality of life through intensive rehabilitation programs. Encompass Health has also continued to expand access to these services by recently opening rehabilitation hospitals in Georgia and Pennsylvania, while announcing new facilities in Idaho and West Virginia to address growing demand for post-acute rehabilitative care.
Option Care Health, Inc. (OPCH - Free Report) supports patients with chronic and complex medical conditions through home and alternate-site infusion services, enabling treatment outside traditional hospital environments. Through a nationwide network of pharmacies, ambulatory infusion suites and clinicians, Option Care Health delivers therapies for chronic inflammatory disorders, neurological diseases, immune deficiencies, serious infections and other conditions requiring ongoing clinical management. Option Care Health combines infusion therapy, nursing support and care coordination to improve patient outcomes while helping health systems and payers manage care more efficiently across the continuum.
DVA’s Price Performance, Valuation and EstimatesShares of DaVita have gained 83.9% year to date compared with the industry’s rise of 9%.
Image Source: Zacks Investment Research
DVA’s forward 12-month P/E of 12.6X is lower than the industry’s average of 17.4X and its five-year median of 12.7X. It has a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DVA’s 2026 earnings per share suggests a 39.8% improvement compared with 2025.
Image Source: Zacks Investment Research
DaVita currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $207.91, moving -1.27% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.09% for the day. Elsewhere, the Dow saw an upswing of 0.14%, while the tech-heavy Nasdaq appreciated by 1.91%.
Shares of the kidney dialysis provider witnessed a gain of 6.96% over the previous month, beating the performance of the Medical sector with its gain of 3.16%, and the S&P 500's gain of 0.29%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is predicted to post an EPS of $4.01, indicating a 35.93% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $3.53 billion, showing a 4.53% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.07 per share and revenue of $14.3 billion. These totals would mark changes of +39.8% and +4.78%, respectively, from last year.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. DaVita HealthCare presently features a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that DaVita HealthCare has a Forward P/E ratio of 13.98 right now. This expresses a discount compared to the average Forward P/E of 18.29 of its industry.
It is also worth noting that DVA currently has a PEG ratio of 0.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.54 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 22:
H&R Block, Inc. (HRB - Free Report) : This DIY tax return preparation services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.
H&R Block has a PEG ratio of 0.53 compared with 0.93 for the industry. The company possesses a Growth Score of B.
DaVita Inc. (DVA - Free Report) : This dialysis services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita has a PEG ratio of 0.68 compared with 2.17 for the industry. The company possesses a Growth Score of B.
Pitney Bowes Inc. (PBI - Free Report) : This technology-driven company offering shipping, mailing, and e-commerce logistics solutions worldwide carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 11% over the last 60 days.
Pitney Bowes has a PEG ratio of 0.79 compared with 0.84 for the industry. The company possesses a Growth Scoreof A.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Learn more about the Growth score and how it is calculated here.
Key Takeaways DaVita's core dialysis execution and Fresenius Medical Care's broader model shape the stock comparison.DaVita raised its 2026 outlook as volume trends, reimbursement gains and cost management improved.FMS leans on transformation savings, renal tech innovation and Interwell value-based care growth. Kidney care continues to evolve as healthcare providers focus on improving outcomes for patients with chronic kidney disease (CKD) and end-stage kidney disease, with DaVita Inc. (DVA - Free Report) and Fresenius Medical Care AG (FMS - Free Report) representing two leading players in the global dialysis and renal care market. DVA is primarily focused on delivering kidney care services through its dialysis and care management operations, while FMS combines dialysis services with a broader portfolio of renal care products and solutions. Both companies operate within the kidney care ecosystem but differ in the scope and structure of their business models.
While DaVita's business is centered on providing dialysis treatment and related kidney care services, Fresenius Medical Care maintains a more diversified presence across renal healthcare through both service delivery and product offerings. As a result, the two companies reflect different approaches to addressing the growing demand for kidney care services worldwide.
As demand for renal care continues to grow amid rising rates of CKD and increasing healthcare needs, this contrast highlights two distinct strategies and raises the question of which company may offer greater long-term opportunity. Let’s take a closer look.
Stock Performance & Valuation: DVA vs. FMSDVA (up 37.7%) has outperformed FMS (up 7.8%) over the past three months. However, in the past year, DaVita stock has gained 49.7% against Fresenius Medical Care’s decline of 14.6%.
Image Source: Zacks Investment Research
Meanwhile, DVA is trading at a forward 12-month price-to-sales (P/E) ratio of 12.6X, below its median of 12.7X over the past five years. FMS’ forward P/E multiple sits at 10.1X, below its five-year median of 12.2X. DVA and FMS both appear to be cheap when compared with the Zacks Medical sector’s average of 19.9X. Currently, DaVita and Fresenius Medical Care stocks have a Value Score of A.
Image Source: Zacks Investment Research
Factors Driving DaVita StockDaVita’s disciplined execution in its core dialysis business remains a key driver. The company delivered stronger-than-expected first-quarter 2026 results, supported by favorable treatment volume trends, reimbursement rate increases and effective cost management. Management highlighted outperformance across treatment volume, revenue per treatment and cost per treatment, reflecting the strength of its operating model. DVA also raised its 2026 operating income and earnings outlook, underscoring confidence in the business momentum.
Integrated Kidney Care (IKC) is emerging as an important long-term growth avenue. DaVita continues to expand its value-based care platform, with a growing number of patients under risk-based arrangements. The business has demonstrated improving clinical outcomes and strong savings generation under CMS kidney care programs, highlighting its ability to create value for both patients and payers while broadening DVA’s opportunities beyond traditional dialysis services.
The company’s ongoing investments in technology and digital infrastructure are strengthening its long-term competitive position. DaVita has been modernizing its data systems and deploying AI-enabled tools across clinical and operational workflows. These initiatives are designed to support caregivers, enhance patient care and improve decision-making, while creating a scalable platform that can drive sustained clinical and operational excellence over time.
Factors Driving Fresenius Medical Care StockFresenius Medical Care’s ongoing transformation efforts are strengthening its profitability profile and operational efficiency. Through the FME Reignite strategy and FME25+ program, the company is optimizing its clinic footprint, streamlining operations and delivering sustainable cost savings across the organization. These initiatives are supporting margin expansion and improved underlying earnings, while positioning FMS to generate stronger long-term returns from its core kidney care business.
Technology and product innovation remain important growth drivers. The company is rapidly expanding the deployment of its 5008X CAREsystem, which supports advanced dialysis therapies and reinforces its leadership in renal care technology. Fresenius Medical Care is also investing in digital solutions such as kinexus, a unified platform that supports remote monitoring, prescription management and workflow integration for home dialysis programs. These initiatives enhance FMS’ ability to support evolving patient care needs, while strengthening its competitive position.
The company’s expanding value-based care business provides another avenue for growth. Through Interwell Health, Fresenius Medical Care has demonstrated strong quality outcomes and savings generation under kidney care programs. Supported by advanced analytics, care coordination capabilities and a broad nephrologist network, the platform helps improve patient outcomes while lowering healthcare costs, strengthening FMS’ position in the shift toward value-based reimbursement models.
Comparing EPS Projections: DVA vs. FMSThe Zacks Consensus Estimate for DVA’s 2026 earnings per share (EPS) suggests a 39.8% improvement from 2025.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for FMS’ 2026 EPS implies a decline of 7.4% from 2025.
Image Source: Zacks Investment Research
Price Target: DaVita vs. Fresenius Medical CareBased on short-term price targets offered by six analysts, the average price target for DaVita is $200.00, implying a decline of 4.6% from the last close.
Image Source: Zacks Investment Research
Based on short-term price targets offered by four analysts, the average price target for Fresenius Medical Care is $24.30, implying an increase of 3.9% from the last close.
Image Source: Zacks Investment Research
Choose DVA Over FMS NowCurrent market sentiment and earnings expectations appear to favor DaVita over Fresenius Medical Care at this stage. Currently, DaVita sports a Zacks Rank #1 (Strong Buy), while Fresenius Medical Care has a Zacks Rank #5 (Strong Sell), reflecting significantly stronger confidence in DVA’s near-term prospects.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Both stocks are trading below their historical valuation levels and at discounts to the broader medical sector, suggesting that investor expectations remain relatively measured. However, DaVita’s valuation appears supported by stronger earnings growth expectations, improving operating performance and continued momentum in its core dialysis and IKC businesses. For investors, this indicates a company that is not only executing well operationally but is also positioned to translate that execution into higher profitability over time.
Fresenius Medical Care, meanwhile, remains in the midst of a broader transformation aimed at improving efficiency, expanding value-based care and advancing innovation across its renal care platform. While these initiatives have the potential to strengthen the business over the long run, investor sentiment remains more cautious given the weaker earnings outlook and the time required for strategic initiatives to translate into sustained financial benefits.
While both companies are well-positioned to benefit from growing demand for kidney care services, DaVita appears better positioned now due to its stronger earnings trajectory and more favorable market sentiment, making it the more attractive choice for investors at current levels.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 24:
H&R Block, Inc. (HRB - Free Report) : This DIY tax return preparation services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.
H&R Block has a PEG ratio of 0.53 compared with 0.95 for the industry. The company possesses a Growth Score of B.
DaVita Inc. (DVA - Free Report) : This dialysis services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita has a PEG ratio of 0.69 compared with 2.20 for the industry. The company possesses a Growth Score of B.
Pitney Bowes Inc. (PBI - Free Report) : This technology-driven company offering shipping, mailing, and e-commerce logistics solutions worldwide carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.6% over the last 60 days.
Pitney Bowes has a PEG ratio of 0.77 compared with 0.83 for the industry. The company possesses a Growth Score of A.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Learn more about the Growth score and how it is calculated here.
DaVita Inc. (DVA - Free Report) : This kidney dialysis company has a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita Inc. has a PEG ratio of 0.65 compared with 2.13 for the industry. The company possesses a Growth Score of B.
Five Below, Inc. (FIVE - Free Report) : This specialty retail company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.
Five Below has a PEG ratio of 1.09 compared with 2.01 for the industry. The company possesses a Growth Score of A.
Pitney Bowes Inc. (PBI - Free Report) : This shipping and mailing services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 11% over the last 60 days.
Pitney Bowes has a PEG ratio of 0.75 compared with 0.86 for the industry. The company possesses a Growth Score of A.
See the full list of top ranked stocks here.
Learn more about the Growth score and how it is calculated here.
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is DaVita (DVA - Free Report) . DVA is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 10.65, while its industry has an average P/E of 16.95. DVA's Forward P/E has been as high as 15.44 and as low as 10.48, with a median of 13.17, all within the past year.
Investors will also notice that DVA has a PEG ratio of 0.83. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DVA's industry currently sports an average PEG of 1.59. DVA's PEG has been as high as 1.09 and as low as 0.69, with a median of 0.87, all within the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. DVA has a P/S ratio of 0.92. This compares to its industry's average P/S of 1.19.
These are just a handful of the figures considered in DaVita's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that DVA is an impressive value stock right now.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Lifetime Brands (LCUT - Free Report) : This company, which is a leading designer, marketer and distributor of kitchenware, tableware, and other home solution products for use in the home, and market in the United States and internationally, has seen the Zacks Consensus Estimate for its current year earnings increasing 19.7% over the last 60 days.
Great Elm Capital Group (GECC - Free Report) : This diversified investment company, which works in line of investment management, financial products and merchant banking, has seen the Zacks Consensus Estimate for its current year earnings increasing 18.3% over the last 60 days.
ARKO (ARKO - Free Report) : This company, which operates a chain of convenience stores in the United States, has seen the Zacks Consensus Estimate for its current year earnings increasing 11.5% over the last 60 days.
Pitney Bowes (PBI - Free Report) : This global technology company, which is powering billions of transactions - physical and digital - in the connected and borderless world of commerce, has seen the Zacks Consensus Estimate for its current year earnings increasing 11% over the last 60 days.
DaVita (DVA - Free Report) : This company, which is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD), has seen the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 day.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: DaVita HealthCare (DVA - Free Report) Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates outpatient dialysis centers and provides related services primarily in its dialysis centers and contracted hospitals across the United States, in addition to offering integrated kidney care services under value-based arrangements. Its services include outpatient dialysis services, hospital inpatient dialysis services and certain ancillary services.
DVA is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 12.98; value investors should take notice.
For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.91 to $15.07 per share. DVA boasts an average earnings surprise of +2.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, DVA should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: DaVita HealthCare (DVA - Free Report) Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates outpatient dialysis centers and provides related services primarily in its dialysis centers and contracted hospitals across the United States, in addition to offering integrated kidney care services under value-based arrangements. Its services include outpatient dialysis services, hospital inpatient dialysis services and certain ancillary services.
DVA is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. DVA has a Momentum Style Score of B, and shares are up 27.1% over the past four weeks.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.91 to $15.07 per share. DVA also boasts an average earnings surprise of +2.4%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DVA should be on investors' short list.
Key Takeaways DaVita posted stronger quarterly revenue and earnings, lifting full-year adjusted EPS outlook.DVA expects higher treatment volumes from favorable patient trends and competitor clinic closures.DVA funds buybacks and IKC growth with strong cash flow, but compensation, insurance and IT costs rise. DaVita Inc.’s (DVA - Free Report) investors have been experiencing some short-term gains from the stock lately. Shares of the Denver, CO-based provider of dialysis services in the United States to patients suffering from chronic kidney failure gained 21.4% in the past three months against the industry’s 5.7% decline. It has also outperformed the sector’s loss of 8.7% and the S&P 500’s gain of 10.9% in the same time frame.
A major recent development of DVA includes the announcement of its first-quarter results last month.
DaVita reported strong first-quarter 2026 results, with improvements in revenues, earnings and operating income. The increase in treatment volume per normalized day and higher reimbursement rates during the quarter were encouraging. DVA also raised its 2026 adjusted operating income and earnings per share (EPS) guidance, reflecting confidence in its business momentum. However, patient care costs and IT-related expenses increased year over year, while revenue per treatment (RPT) declined sequentially. Rising operating costs may continue to weigh on margins going forward, which does not bode well for the stock.
DVA's Three Months Price Comparison
Image Source: Zacks Investment Research
Over the past three months, the stock’s performance has remained strong, outperforming its peers like Fresenius Medical Care AG (FMS - Free Report) . However, it underperformed its peer, Outset Medical, Inc. (OM - Free Report) . Fresenius Medical and Outset Medical’s shares have lost 10.8% and gained 43.6%, respectively, in the same time frame.
For 2026, DaVita expects RPT to reflect growth of 1%-2%, while treatment volume is expected to be higher compared with 2025.
Adjusted EPS from continuing operations for the full year is projected to be in the range of $14.10-$15.20. The Zacks Consensus Estimate for the metric is currently pegged at $15.07.
For the second quarter of 2026, the Zacks Consensus Estimate for adjusted EPS is pegged at $4.01.
DVA’s Strengthening Core Dialysis FranchiseDaVita continues to benefit from annual reimbursement increases across Medicare and commercial contracts, supporting revenue growth despite normal seasonal fluctuations. The company’s large dialysis network and exposure to higher-paying commercial plans provide a stable revenue base, while early ACA enrollment trends have been better than management's prior expectations, potentially easing previously anticipated reimbursement pressures.
Treatment volumes exceeded management’s expectations in the first quarter of 2026, aided by favorable patient trends and lower-than-anticipated mortality. DVA also expects to benefit from patient transfers associated with competitor clinic closures, prompting it to raise its full-year treatment growth outlook. Sustained volume growth remains a key driver of revenue and earnings expansion.
Better labor productivity also helped the company keep patient-care costs below expectations, highlighting the effectiveness of DaVita’s operating model. The company is also investing in digital infrastructure and AI-enabled tools to improve scheduling, workforce utilization and administrative efficiency. These initiatives are expected to support DVA’s margin durability and create additional operating leverage over time.
DaVita’s Value-Based Care and Cash Flow StrengthIntegrated Kidney Care (IKC) remains an important long-term growth avenue for DaVita. The business continues to demonstrate strong performance in value-based care programs through improved quality outcomes and savings generation. As DVA expands its risk-based care arrangements and strengthens physician partnerships, it is building a more diversified and sustainable kidney-care ecosystem.
Strong operating and free cash flow generation provides DaVita with ample financial flexibility. The company has remained aggressive in repurchasing shares while maintaining leverage within its target range, underscoring management’s disciplined capital allocation strategy. Consistent cash generation and buybacks continue to enhance shareholder value and support investor sentiment toward the stock.
Challenges Ahead of DVAA key challenge for DaVita is the continued rise in operating expenses, particularly compensation, insurance and technology-related costs, which could pressure margins despite ongoing productivity improvements. Another concern is DVA’s dependence on commercial insurance plans for a significant share of its profits. Any decline in commercially insured patients, unfavorable reimbursement changes or shifts in plan mix could materially affect revenue growth and profitability, given the substantial gap between commercial and government reimbursement rates.
DaVita Stock’s ValuationDVA’s forward 12-month P/S of 0.83X is lower than the industry’s average of 2.67X but is higher its five-year median of 0.79X.
Image Source: Zacks Investment Research
Fresenius Medical and Outset Medical’s forward 12-month P/S currently stand at 0.47X and 0.71X, respectively, in the same time frame.
DVA’s Estimate MovementEstimates for DaVita’s 2026 earnings have moved 6.4% north to $15.07 in the past 60 days.
Image Source: Zacks Investment Research
Estimates for Fresenius Medical’s 2026 EPS have moved 7.4% south to $2.24 in the past 60 days.
Estimates for Outset Medical’s 2026 loss per share have widened from $2.83 to $2.88 in the past 60 days.
Our Final Take on DaVitaDaVita, a Zacks Rank #1 (Strong Buy) stock, remains well positioned to benefit from its leadership in the U.S. dialysis market, improving treatment volumes and expanding value-based care initiatives. The company’s strong operational execution, productivity gains and ongoing technology investments are supporting earnings growth while enhancing its long-term competitive position. Its IKC platform also offers an additional growth avenue beyond traditional dialysis services. You can see the complete list of today’s Zacks #1 Rank stocks here.
However, investors should monitor rising labor, insurance and technology-related expenses, which could pressure margins over time. DVA’s reliance on commercial payors for a significant portion of its profits also exposes it to reimbursement and insurance-mix risks.
From a valuation standpoint, the stock appears reasonably priced relative to its business fundamentals and growth prospects. The current valuation suggests that the market has yet to fully recognize the benefits of improving treatment volumes, operational efficiencies and disciplined capital allocation. This leaves room for further upside if management continues to execute effectively.
For existing shareholders, the stock remains an attractive long-term holding. Prospective investors can also consider building positions, as DaVita’s improving fundamentals, favorable earnings momentum suggest that the recent rally may not yet be over. The favorable Zacks Style Score with a Growth Score of B suggests continued uptrend potential for DVA.
A month has gone by since the last earnings report for DaVita HealthCare (DVA - Free Report) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is DaVita HealthCare due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
DaVita Q1 Earnings & Revenue Beat Estimates, Margins ExpandDaVita delivered adjusted earnings per share from continuing operations of $2.87 in the first quarter of 2026, up 43.5% year over year. The figure surpassed the Zacks Consensus Estimate by 19.1%.
GAAP earnings per share from continuing operations for the quarter was also $2.87, reflecting an uptick of 43.5% year over year.
DaVita’s Revenues in DetailRevenues of $3.42 billion in the first quarter increased 5.9% year over year. The figure topped the Zacks Consensus Estimate by 3.5%.
RPT in the first quarter of 2026 was $417.6 million, up 4.4% year over year, but down 1.2% sequentially. Per management, the sequential decline was primarily the result of the typical first-quarter headwind from patient-pay responsibility.
DVA’s Segment DetailsDaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues.
The dialysis patient service revenues were $3.27 billion, up 5.5% year over year.
Other revenues were $142.8 million, up 18.4% from the year-ago quarter’s figure.
Per management, the total U.S. dialysis treatments for the first quarter were 7,029,525 or 91,650 per day, on average. This represents a per-day increase of 0.05% on a sequential basis. Normalized non-acquired treatment increased 0.1% year over year in the first quarter of 2026.
As of March 31, 2026, DaVita provided dialysis services to around 296,300 patients at 3,262 outpatient dialysis centers, of which 2,666 were U.S. centers while 596 were located across 14 other countries.
As of March 31, 2026, DVA had approximately 62,600 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.4 billion in annualized medical spend. The company also had an additional 6,300 patients in other integrated care arrangements.
DaVita’s Margin DetailsIn the quarter under review, DaVita’s gross profit increased 9.1% year over year to $1.07 billion. The gross margin expanded 90 basis points (bps) to 31.4%.
General & administrative expenses climbed 12.8% year over year to $421.9 million.
Adjusted operating profit totaled $651.4 million, reflecting a 6.8% increase from the prior-year quarter’s level. Adjusted operating margin in the first quarter expanded 15 bps to 19.1%.
DVA’s Financial PositionDaVita exited first-quarter 2026 with cash and cash equivalents and short-term investments of $666.5 million compared with $700.7 million at the fourth quarter of 2025-end. Total debt (including the current portion) at the end of first-quarter 2026 was $10.63 billion compared with $10.27 billion at the end of the fourth quarter of 2025.
Net cash provided by operating activities at the end of first-quarter 2026 was $320.8 million compared with $180 million a year ago.
During the three months ended March 31, 2026, DVA repurchased 3 million shares for $403 million. Subsequent to March 31, 2026, through May 5, 2026, the company has repurchased 2 million shares of its common stock for $302 million.
DaVita’s GuidanceDaVita has revised its outlook for 2026.
For 2026, DVA continues to expect RPT to reflect growth of 1%-2%, while treatment volume is expected to be higher compared with 2025.
Adjusted earnings per share from continuing operations for the full year is now projected to be in the range of $14.10-$15.20, up from the prior outlook of $13.60-$15.00. The Zacks Consensus Estimate currently stands at $14.16.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 5.58% due to these changes.
VGM ScoresAt this time, DaVita HealthCare has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock has a grade of A on the value side, putting it in the top 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise DaVita HealthCare has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry PlayerDaVita HealthCare is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, Quest Diagnostics (DGX - Free Report) , a stock from the same industry, has gained 2.4%. The company reported its results for the quarter ended March 2026 more than a month ago.
Quest Diagnostics reported revenues of $2.9 billion in the last reported quarter, representing a year-over-year change of +9.2%. EPS of $2.50 for the same period compares with $2.21 a year ago.
Quest Diagnostics is expected to post earnings of $2.81 per share for the current quarter, representing a year-over-year change of +7.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.
Quest Diagnostics has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
Key Takeaways DaVita provides dialysis via outpatient centers, hospitals and home hemo/peritoneal options.DaVita's IKC coordinates advanced CKD/ESKD care; CKCC showed progress in quality and savings.FMS exceeded 100,000 5008X treatments, while OM preps next-gen Tablo cleared under the FDA's 2025 cyber rules DaVita Inc. (DVA - Free Report) is a key player in the dialysis space, providing comprehensive kidney care services to patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company’s core business centers on delivering dialysis treatment through a broad network of outpatient dialysis centers, hospital-based services and home-based modalities, including home hemodialysis and peritoneal dialysis. By supporting patients across multiple care settings — from dialysis clinics and hospitals to home environments — DVA plays an important role in ensuring access to life-sustaining renal care while helping patients navigate different treatment options throughout their kidney health journey.
The company has also expanded beyond traditional dialysis delivery to strengthen its presence across the broader kidney care continuum. Through its Integrated Kidney Care (IKC) platform, DaVita coordinates care for patients with advanced CKD and ESKD, working alongside physicians and healthcare providers to improve clinical outcomes and support earlier intervention. Recent results from the Comprehensive Kidney Care Contracting (CKCC) program demonstrated continued progress in quality and savings measures, highlighting the growing role of value-based kidney care models in the dialysis industry.
DaVita continues to invest in technology and operational capabilities that support its dialysis network. During 2026, the company highlighted ongoing investments in digital infrastructure and AI-enabled tools, including new scheduling technologies designed to improve care delivery and operational efficiency. These initiatives reinforce DVA’s position as a leading dialysis services provider while supporting the industry's broader shift toward integrated, patient-centered kidney care.
FMS & OM Expanding Innovation Across Dialysis CareFresenius Medical Care AG (FMS - Free Report) is a renowned player in the dialysis ecosystem, combining dialysis care delivery with the manufacture of dialysis products and equipment. FMS provides treatment for CKD and end-stage renal disease through its Care Delivery, Care Enablement and Value-Based Care segments.
In 2026, Fresenius Medical Care accelerated the rollout of its 5008X CAREsystem in the United States, reaching around 100 clinics and surpassing 100,000 treatments. Fresenius Medical Care also launched kinexus, a unified global digital platform that supports home dialysis programs by integrating remote therapy monitoring, prescription management and supply ordering across peritoneal dialysis and home hemodialysis therapies.
Outset Medical, Inc. (OM - Free Report) is directly involved in the dialysis space through its Tablo Hemodialysis System, a technology platform designed to simplify dialysis delivery across hospitals, clinics and home settings. Outset Medical focuses on improving dialysis outcomes while reducing cost and complexity for providers and patients.
During 2026, Outset Medical continued expanding Tablo adoption across acute and post-acute care facilities and prepared for the launch of its next-generation Tablo platform. The new system, which OM believes is the first dialysis system cleared under the FDA’s 2025 cybersecurity requirements, incorporates hardware and software enhancements aimed at improving performance, reliability and patient safety while supporting broader dialysis care delivery.
DVA’s Price Performance, Valuation and EstimatesShares of DaVita have gained 71.6% year to date compared with the industry’s rise of 5.3%.
Image Source: Zacks Investment Research
DVA’s forward 12-month P/E of 11.8X is lower than the industry’s average of 16.9X and its five-year median of 12.7X. It has a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DVA’s 2026 earnings per share suggests a 39.8% improvement compared with 2025.
Image Source: Zacks Investment Research
DaVita currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
DaVita (DVA - Free Report) is a stock many investors are watching right now. DVA is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock is trading with P/E ratio of 10.65 right now. For comparison, its industry sports an average P/E of 16.81. DVA's Forward P/E has been as high as 15.44 and as low as 10.48, with a median of 13.17, all within the past year.
Investors should also note that DVA holds a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DVA's PEG compares to its industry's average PEG of 1.31. Over the last 12 months, DVA's PEG has been as high as 1.09 and as low as 0.69, with a median of 0.87.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. DVA has a P/S ratio of 0.92. This compares to its industry's average P/S of 1.18.
These are only a few of the key metrics included in DaVita's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, DVA looks like an impressive value stock at the moment.
Key Takeaways DVA served 296,300 patients through 3,262 outpatient dialysis centers worldwide as of March 31, 2026.DaVita's IKC platform covered 62,600 patients and represents about $5.4 billion in annualized medical spend.BAX backs renal care via its medical products, while RMTI signed a 3-year supply deal with Heritage Dialysis. DaVita Inc. (DVA - Free Report) , a well-known kidney care services provider, is focused on delivering dialysis treatment and integrated care solutions for patients with chronic and end-stage kidney disease. As of March 31, 2026, the company was serving 296,300 patients through 3,262 outpatient dialysis centers worldwide, underscoring its significant presence in the global renal care market. In first-quarter 2026, DVA delivered more than 7 million dialysis treatments and continued to expand its Integrated Kidney Care (IKC) platform, which covered 62,600 patients in risk-based care arrangements.
Beyond its core dialysis operations, DaVita is increasingly emphasizing coordinated and value-based care to improve outcomes for kidney disease patients. The company reported continued momentum in its IKC business, which represents approximately $5.4 billion in annualized medical spend under risk-based arrangements. This reflects DVA's broader strategy of managing patient care across the kidney disease space while supporting long-term healthcare efficiency and quality outcomes.
Recent developments highlight the company's focus on innovation and care coordination. DaVita reported year-over-year improvements across key measures in the Comprehensive Kidney Care Contracting (CKCC) program and generated the highest aggregate savings among participants in first-quarter 2026. DVA is also investing in technology-driven initiatives, including the rollout of its AI-enabled ScheduleHub tool, designed to optimize patient scheduling and staffing while enhancing operational efficiency and supporting clinical excellence.
BAX & RMTI Supporting the Broader Renal Care EcosystemBaxter International Inc. (BAX - Free Report) remains connected to the renal care ecosystem through products that continue to be used in kidney dialysis centers and other healthcare settings. While Baxter completed the sale of its Kidney Care business, now known as Vantive, in January 2025, BAX still serves healthcare providers through its broad portfolio of medical products and therapies.
Recent developments reflect Baxter’s ongoing focus on operational improvement and innovation, with the company advancing connected-care offerings, including smart bed systems, patient monitoring technologies, infusion systems and respiratory health devices, while continuing to support providers across a range of care settings.
Rockwell Medical, Inc. (RMTI - Free Report) is a dedicated renal care company focused on developing, manufacturing and distributing hemodialysis products for dialysis providers worldwide. Rockwell Medical supplies a broad portfolio of dialysis concentrates and related products that support patients with end-stage kidney disease.
Recent developments include Rockwell Medical's new three-year supply agreement with Heritage Dialysis and the renewal of its agreement with aQua Dialysis, strengthening its presence in both in-center and home dialysis markets. RMTI also continues to focus on operational improvements, profitability and long-term growth within the dialysis industry.
DVA’s Price Performance, Valuation and EstimatesShares of DaVita have gained 74.4% year to date compared with the industry’s rise of 8.5%.
Image Source: Zacks Investment Research
DVA’s forward 12-month P/E of 11.9X is lower than the industry’s average of 17.4X and its five-year median of 12.7X. It has a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DVA’s 2026 earnings per share suggests a 39.8% improvement compared with 2025.
Image Source: Zacks Investment Research
DaVita currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 11:
Priority Technology Holdings, Inc. (PRTH - Free Report) : This payment technology company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 6% over the last 60 days.
Priority Technology Holdings has a price-to-earnings ratio (P/E) of 4.89 compared with 9.70 for the industry. The company possesses a Value Scoreof A.
DaVita Inc. (DVA - Free Report) : This kidney dialysis company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 6.4% over the last 60 days.
DaVita has a price-to-earnings ratio (P/E) of 13.15 compared with 26.40 for the industry. The company possesses a Value Score of A.
Bread Financial Holdings, Inc. (BFH - Free Report) : This fintech company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 12.1% over the last 60 days.
Bread Financial Holdings has a price-to-earnings ratio (P/E) of 8.90 compared with 22.84 for the S&P. The company possesses a Value Score of A.
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
DaVita HealthCare (DVA - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for DaVita HealthCare basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for DaVita HealthCare imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for DaVita HealthCareThis kidney dialysis provider is expected to earn $15.07 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for DaVita HealthCare. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.4%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of DaVita HealthCare to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
DaVita HealthCare (DVA - Free Report) closed at $203.83 in the latest trading session, marking a +2.66% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.75%. On the other hand, the Dow registered a gain of 1.86%, and the technology-centric Nasdaq increased by 2.54%.
The kidney dialysis provider's shares have seen an increase of 0.22% over the last month, not keeping up with the Medical sector's gain of 3.73% and outstripping the S&P 500's loss of 1.63%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. In that report, analysts expect DaVita HealthCare to post earnings of $4.01 per share. This would mark year-over-year growth of 35.93%. Our most recent consensus estimate is calling for quarterly revenue of $3.53 billion, up 4.53% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $15.07 per share and revenue of $14.3 billion, which would represent changes of +39.8% and +4.78%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DaVita HealthCare is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that DaVita HealthCare has a Forward P/E ratio of 13.18 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.54.
Meanwhile, DVA's PEG ratio is currently 0.65. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Outpatient and Home Healthcare industry held an average PEG ratio of 1.52.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 46, placing it within the top 19% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20
Stock Market Finds Rocket Fuel From Trump Canceling Iran Strikes; SpaceX Debut On Deck
Two AI Titans Flash Entries As Rocket Lab Readies For Launch Bank of Montreal (BMO), Intercorp Financial Services (IFS), DaVita (DVA) and Astronics (ATRO) reached new highs Friday, as the stock market looked to add to a rebound following heavy, recent losses. All four stocks are in Investor's Business Daily's New Highs list, which shows leading names making new 52-week highs. Stocks at new highs, especially during weak markets, can be some…
